Page last updated: 2024-09-05

sb 203580 and allicin

sb 203580 has been researched along with allicin in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(allicin)
Trials
(allicin)
Recent Studies (post-2010) (allicin)
3,48941,13760129339

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)allicin (IC50)
Mitochondrial 2-oxodicarboxylate carrierHomo sapiens (human)0.011

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cha, JH; Cha, SH; Cho, WH; Choi, CH; Choi, YJ1

Other Studies

1 other study(ies) available for sb 203580 and allicin

ArticleYear
Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway.
    Oncology reports, 2012, Volume: 28, Issue:1

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Butadienes; Caspases; Catalase; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Disulfides; Extracellular Signal-Regulated MAP Kinases; Glioblastoma; Humans; Imidazoles; MAP Kinase Signaling System; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfinic Acids

2012